Navigation Links
Daytrana (methylphenidate transdermal system) Provides Significant,Effectiveness in ADHD Symptom Relief in Both Boys and Girls

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plc announced today that DAYTRANA(TM) (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, had significant efficacy in reducing the symptoms of ADHD in both male and female children aged 6 to 12 years, according to clinical trial results reported at the American Psychiatric Association (APA) annual meeting in San Diego.

"Few clinical studies have examined gender differences in the response to ADHD treatments. Our study documented that DAYTRANA offered a favorable safety profile and was an effective ADHD treatment in both boys and girls," said Robert Findling, M.D., lead investigator and Professor of Psychiatry at and Director of the Division of Adolescent and Child Psychiatry at University Hospitals Case Medical Center. "The study provides a platform to open a dialogue about gender and ADHD."

Approximately 4.4 million U.S. children aged 4 to 17 years -- about 7.8 percent of all school-age children -- have been diagnosed with ADHD at some point in their lives, according to the U.S. Centers for Disease Control and Prevention (CDC). Studies estimated that 11.0 percent of boys have been diagnosed with ADHD in contrast to only 4.4 percent of girls. Experts believe that girls with ADHD are underdiagnosed and, therefore, undertreated.

Shire's DAYTRANA is the first and only patch medication approved by the U.S. Food and Drug Administration (FDA) to treat the symptoms of ADHD in children aged 6 to 12 years. DAYTRANA is available in four dosage strengths - 10 mg, 15 mg, 20 mg and 30 mg - all designed for once-daily use. When worn for the recommended nine hours, efficacy has been demonstrated from the first time point measured (two hours) through the 12-hour time point. Because Daytrana is a patch, physicians may recommend that patients shorten the wear time if shorter duration of effect is desired or t
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. 12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. XTL Provides Update on Phase I Clinical Trial of XTL-2125
4. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
5. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
6. NicOx Provides an Update on the Phase 2a Study for NCX 1000 Conducted With Axcan
7. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
8. Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma
9. New Analysis of Data from WHI Provides Reassurance With Respect to Coronary Heart Disease For Newly Menopausal Women Considering Hormone Therapy
10. Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer
11. Novavax Vaccine Provides Robust Immune Response, Pre-Clinical Data Show
Post Your Comments:
(Date:7/31/2015)... 2015  Physicians and payers alone do not ... Patients are better informed and getting increasingly involved ... This shift in power is reshaping the healthcare ... marketing. As part of this evolving ... important to educate, communicate and engage patients throughout ...
(Date:7/31/2015)... , July 31, 2015  In today,s ever-changing marketplace, ... are increasingly mobile, increasingly connected, and increasingly impatient with ... of customer interaction channels and tools is driving call ... media. According to research by benchmarking ... counter (OTC) segment in a call center study realize ...
(Date:7/31/2015)... , July 31, 2015  Seeger Weiss LLP is reporting ... issued a warning letter to C.R. Bard, the manufacturer of ... adequate strides to correct violations the agency found at two ... violations after the FDA cited them during Inspectional Observations that ... Bard,s Tempe, AZ , location and on ...
Breaking Medicine Technology:Consumers Forcing Pharmaceutical Industry to Shift its Marketing Focus from Products to Patients 2Best Practices in Building World-Class Consumer & Over-the-Counter Call Centers 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 2Seeger Weiss LLP Reports That The FDA Has Issued A Warning Letter To IVC Filter Manufacturer, C.R. Bard 3
... presented at the 10th International Kidney Cancer Symposium ... pretreatment blood-based test, VeriStrat, was able to stratify ... combination of two targeted therapies, sunitinib (Sutent®) and ... tested VeriStrat Good had significantly longer progression free ...
... 14, 2011 Reata Pharmaceuticals, Inc. announced Friday a ... company,s lead program, bardoxolone methyl, and to continue advancing ... the following executives: Paul Audhya, MD, ... Hilary Malone, Ph.D., as Vice President and ...
Cached Medicine Technology:VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 2VeriStrat® Results Correlate with Survival Outcomes in Kidney Cancer Patients 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award ... fat reduction in New York. Due to its unparalleled level of experience for ... patients travel to New York to get their non-surgical skin tightening and body shaping ...
(Date:7/31/2015)... Atlanta, GA (PRWEB) , ... July 31, 2015 ... ... the five new industry players to know in predictive health analytics , ... machine learning technologies. The firm creates predictive software that targets patient and population ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last week, the Mesothelioma ... store can be accessed by visiting http://www.curemeso.org/store . , “Our new store ... best part: whenever a product is purchased, the Meso Foundation receives a $5.00 ...
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight ... Memphis on October 3, 2015. The Ride to Fight On is a cycling fundraiser ... Methodist Healthcare, The West Clinic and The University of Tennessee Health Science Center. A ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical ... PRO this week. Zeltiq Aesthetics released this new applicator in the United States ... for treating the outer thighs. The original applicator required a 2 hour treatment ...
Breaking Medicine News(10 mins):Health News:Jvion Showcased as Leader in the Predictive Analytic Market 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... Inc. ("Astellas") recently hired Walt Johnston as vice president ... president of marketing & sales, Johnston will be responsible ... and development products for the United States business."Walt is ... values. We are excited to add him to our ...
... division of Elsevier, would like to announce the ... Evidence-Based Addiction Treatment by Peter Miller, PhD. ... effectiveness in the field of addictions treatment is ... Inconsistent practices based solely on clinical intuition rather ...
... An experimental drug derived from cottonseed shows promise ... the most lethal brain cancer, said researchers at the ... results are from a Phase II clinical trial of ... cottonseed that overcomes the abnormal growth patterns of tumor ...
... The Initial Rush is On, So Consumers Should Get This Deliciously ... One of the most widely anticipated product launches of the season ... such as phones and video games, but consumers can,t wait to ... (R) Special K ...
... (NYSE Amex: CXM ) and its subsidiary ... "Phase 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment ... Trials Symposium at the American Society of Gene Therapy ... 27, 2009. Dr. Barbara K. Sosnowski, Cardium,s Vice ...
... Mass., May 28 Echo Therapeutics, Inc. (OTC ... signed a license agreement with Ferndale Pharma Group ... to develop, market, sell and distribute Echo,s Prelude(TM) ... preparation prior to the application of topical 4% ...
Cached Medicine News:Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 2Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 3Health News:Special K(R) Brand Shakes Things Up with New Weight-Management Protein Shake 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 2Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 3Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 5Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 6Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 7Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 8Health News:Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine 2Health News:Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine 3Health News:Echo Therapeutics Licenses Needle-Free Prelude SkinPrep System to Ferndale Pharma for Enhanced Delivery of Topical Lidocaine 4
... Tri-Active is the result of ... the combination of three different methods ... to your skin. This treatment is ... of cellulite through the combined action ...
... is a CO2 laser system with CW ... for dealing with all therapeutic application in ... supplies medium-to-high intensities in super-pulsed mode, designed ... surgery. It is also capable of supplying ...
... the latest evolution of Smartepil family by ... system for epilation and transdermic vascular treatments. ... modern software, Smartepil II Plus allows for ... respect of the patients social life. The ...
... offers a new and efficient method applied ... Springing from ongoing research and development with ... just a light source, but rather a ... represents new horizons in pulsed-light-based technology, the ...
Medicine Products: